Characterization and Comparison of the Gene Expression Profiles of Copaxone® and Mylan Glatiramer Acetate

被引：0
|
作者：
Smith, Jeffrey [1 ]
Hsu, Chun-Nan [2 ]
Lipsky, Peter [3 ]
机构：
[1] Mylan Labs, Morgantown, WV USA
[2] UC San Diego, Dept Biomed Informat, La Jolla, CA USA
[3] AMPEL BioSolut, Charlottesville, VA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1.376
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Glatiramer acetate (copaxone) influences at different phases of pathogenesis of multiple sclerosis
    Schmidt, TE
    Zhuchenko, TD
    Yakhno, NN
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2003, : 79 - 82
  • [22] Determinants of treatment persistence with glatiramer acetate in the French national Copaxone registry
    Lebrun-Frenay, C.
    Moulignier, A.
    Pierrot-Deseilligny, C.
    Moreau, T.
    Salin, B.
    Monchecourt, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 331 - 332
  • [23] Glatiramer acetate -: Copolymer-1 -: Copaxone® -: Treatment of multiple sclerosis
    不详
    DRUGS OF THE FUTURE, 2001, 26 (02) : 180 - 181
  • [24] Reduction of free radicals in multiple sclerosis:: effect of glatiramer acetate (Copaxone®)
    Iarlori, C.
    Gambi, D.
    Lugaresi, A.
    Patruno, A.
    Felaco, M.
    Salvatore, M.
    Speranza, L.
    Reale, M.
    MULTIPLE SCLEROSIS, 2008, 14 (06): : 739 - 748
  • [25] Evaluation of the potential newborn exposure to glatiramer acetate (Copaxone) via lactation
    Ashkenazi, N.
    Hallak, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 467 - 467
  • [26] Genomic profiling and in vivo rat toxicity characterization of Copaxone and the Synthon European follow-on glatiramer acetate product
    Kolitz, S.
    Ashkenazi, N.
    Timan, B.
    Zhang, J.
    Funt, J.
    Beriozkin, O.
    Konya, A.
    Alexander, J.
    Loupe, P.
    Vardi, M.
    Weinstein, V.
    Melamed-Gal, S.
    Grossman, I.
    Zeskind, B.
    Nock, S.
    Hayden, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 940 - 941
  • [27] Mechanisms of Glatiramer Acetate (Copaxone®) signal transduction on T cells in vitro.
    Raddassi, K
    Imitola, J
    Bourcier, K
    Khoury, SJ
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S46 - S47
  • [28] Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis
    Horani, Amjad
    Muhanna, Nidal
    Pappo, Orit
    Melhem, Alaa
    Alvarez, Carlos E.
    Doron, Sarit
    Wehbi, Wehbi
    Dimitrios, Karussis
    Friedman, Scott L.
    Safadi, Rifaat
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2007, 292 (02): : G628 - G638
  • [29] Gene Expression Profiles Following One-Year Treatment with Glatiramer Acetate 20mg and 40mg (GA, Copaxone®) in Relapsing-Remitting Multiple Sclerosis Patients
    Achiron, Anat
    Belker, Tal
    Yemini, Einav
    Sonis, Polina
    Gurevich, Michael
    NEUROLOGY, 2009, 72 (11) : A38 - A39
  • [30] Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis - A pilot study
    Farina, C
    Wagenpfeil, S
    Hohlfeld, R
    JOURNAL OF NEUROLOGY, 2002, 249 (11) : 1587 - 1592
12345